Can plasma HHV8 viral load be used to differentiate multicentric Castleman disease from Kaposi sarcoma?

被引:16
|
作者
Sayer, R. [2 ,3 ]
Paul, J. [4 ]
Tuke, P. W. [5 ]
Hargreaves, S. [2 ]
Noursadeghi, M. [3 ,6 ]
Tedder, R. S. [5 ]
Grant, P. [4 ]
Edwards, S. G. [2 ,3 ]
Miller, R. F. [1 ,2 ,3 ,7 ]
机构
[1] UCL, Mortimer Market Ctr, Div Populat Hlth, Ctr Sexual Hlth & HIV Res,Res Dept Infect & Popul, London WC1E 6JB, England
[2] Mortimer Market Ctr, Camden Provider Serv, London, England
[3] Univ Coll London Hosp NHS Trust, London, England
[4] Univ Coll London Hosp, Dept Virol, London, England
[5] Hlth Protect Agcy, Ctr Infect, Blood Borne Viruses Unit, Virus Reference Dept, London, England
[6] UCL, Div Infect & Immun, London WC1E 6JB, England
[7] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England
关键词
HIV; AIDS; human herpesvirus 8; HHV8; Kaposi sarcoma; Castleman disease; lymphoma; fever; DNA load; multicentric; ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; REAL-TIME PCR; DNA-SEQUENCES; PERIPHERAL-BLOOD; LYMPHOPROLIFERATIVE DISORDERS; HERPESVIRUS; HUMAN-HERPESVIRUS-8; TRANSPLANTATION; QUANTIFICATION;
D O I
10.1258/ijsa.2011.010464
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We measured plasma human herpesvirus 8 (HHV8) DNA load in consecutive patients presenting with HIV-associated multicentric Castleman disease (MCD) and in contemporaneous patients who had Kaposi sarcoma (KS), lymphoma or other diagnoses. All 11 patients with MCD had detectable plasma HHV8 DNA compared with 18 (72%) of 25 patients with KS, none with lymphoma and one of 38 patients with other diagnoses. Detectable plasma HHV8 DNA levels were higher among MCD patients, median (interquartile range [IQR]) = 43,500 (5200-150,000) copies/mL, when compared with those with KS, median (IQR) = 320 (167-822) copies/mL and those with lymphoma and other diagnoses (one-way analysis of variance; P = 0.0303). Using receiver operating characteristic analysis, a cut-off of >1000 copies HHV8 DNA/mL of plasma helped to discriminate between MCD and other diagnoses, with a specificity of 94.7% and a negative predictive value of 97.3%. The level of HHV8 viraemia, while not diagnostic, may aid discrimination between patients with MCD and those with KS and other systemic illnesses.
引用
收藏
页码:585 / 589
页数:5
相关论文
共 50 条
  • [41] HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma
    Nicoli, Paolo
    Familiari, Ubaldo
    Bosa, Marco
    Allice, Tiziano
    Mete, Francesca
    Morotti, Alessandro
    Cilloni, Daniela
    Saglio, Giuseppe
    Guerrasio, Angelo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (03) : 392 - 396
  • [42] Immunophenotypic (IP) analysis of the kaposi's sarcoma herpesvirus (KSHV; HHV-8) infected B cells in HIV plus multicentric castleman's disease (MCD)
    Khanani, F.
    Hyjek, E.
    Tam, W.
    Liu, Y. F.
    Rengifo, T.
    Cesarman, E.
    Knowles, D. M.
    Chadburn, A.
    MODERN PATHOLOGY, 2007, 20 : 248A - 248A
  • [43] Immunophenotypic (IP) analysis of the Kaposi's sarcoma herpesvirus (KSHV; HHV-8) infected B cells in HIV plus multicentric Castleman's disease (MCD)
    Khanani, F.
    Hyjek, E.
    Tam, W.
    Liu, Y. F.
    Rengifo, T.
    Cesarman, E.
    Knowles, D. M.
    Chadburn, A.
    LABORATORY INVESTIGATION, 2007, 87 : 248A - 248A
  • [44] No HHV8 in non-Kaposi's sarcoma mucocutaneous lesions from immunodeficient HIV-positive patients
    Uthman, A
    Brna, C
    Weninger, W
    Tschachler, E
    LANCET, 1996, 347 (9016): : 1700 - 1701
  • [45] Use of plasma human herpesvirus 8 (HHV8) viral load measurement: a joint evaluation of practice in 3 HIV units
    Nugent, D.
    Chung, E.
    Webster, D.
    Mabayoje, D.
    Bouzidi, K. E.
    O'Sullivan, A.
    Ainsworth, J.
    Miller, R.
    HIV MEDICINE, 2016, 17 : 49 - 49
  • [46] Kaposi's sarcoma-associated herpesvirus (KSHV): A new viral pathogen associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease
    Said, J
    WESTERN JOURNAL OF MEDICINE, 1997, 167 (01): : 37 - 38
  • [47] HHV-8 viral load in HIV-infected patients with primary effusion lymphoma and Kaposi's sarcoma
    Tedeschi, R
    Bidoli, E
    Enbom, M
    Linde, A
    Dillner, J
    Simonelli, C
    De Paoli, P
    XIV INTERNATIONAL AIDS CONFERENCE: BASIC SCIENCES, 2002, : 35 - 38
  • [48] Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient
    Murphy, C.
    Hawkes, E.
    Chionh, F.
    Chong, G.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (01) : 111 - 114
  • [49] TWO HHV8-RELATED ILLNESSES IN A HIV-NEGATIVE PATIENT: KAPOSI'S SARCOMA AND MULTICENTRIC CASTLEMAN'S DISEASE. RESPONSE TO TREATMENT WITH RITUXIMAB AND CHOP
    Pastor, M. A.
    Vasco, B.
    Mosquera, J. M.
    Deben, G.
    Bautista, P.
    Requena, L.
    ACTAS DERMO-SIFILIOGRAFICAS, 2006, 97 (06): : 385 - 390
  • [50] KSHV/HHV8-associated primary cutaneous plasmablastic lymphoma in a patient with Castleman's disease and Kaposi's sarcoma
    Liu, Wenhua
    Lacouture, Mario E.
    Jiang, Jesse
    Kraus, Madeleine
    Dickstein, Jerome
    Soltani, Keyoumars
    Shea, Christopher R.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2006, 33 : 46 - 51